239 related articles for article (PubMed ID: 15014021)
1. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Yoh K; Ishii G; Yokose T; Minegishi Y; Tsuta K; Goto K; Nishiwaki Y; Kodama T; Suga M; Ochiai A
Clin Cancer Res; 2004 Mar; 10(5):1691-7. PubMed ID: 15014021
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
[TBL] [Abstract][Full Text] [Related]
3. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Kim YH; Ishii G; Goto K; Ota S; Kubota K; Murata Y; Mishima M; Saijo N; Nishiwaki Y; Ochiai A
Lung Cancer; 2009 Jul; 65(1):105-11. PubMed ID: 19036469
[TBL] [Abstract][Full Text] [Related]
4. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
[TBL] [Abstract][Full Text] [Related]
5. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
[TBL] [Abstract][Full Text] [Related]
6. [Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer].
Hu Y; Lin DM; Cheng SJ; Liu YN; Feng FY
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(37):2611-4. PubMed ID: 17198586
[TBL] [Abstract][Full Text] [Related]
7. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
Li J; Li ZN; Yu LC; Bao QL; Wu JR; Shi SB; Li XQ
Lung Cancer; 2010 Jul; 69(1):116-22. PubMed ID: 19875192
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
9. [Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC].
Hu Y; Feng FY; Cheng SJ; Gao YN; Xiao T; Liu YN
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):750-2. PubMed ID: 17366786
[TBL] [Abstract][Full Text] [Related]
10. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.
Li XQ; Li J; Shi SB; Chen P; Yu LC; Bao QL
Int J Biol Markers; 2009; 24(4):230-7. PubMed ID: 20082278
[TBL] [Abstract][Full Text] [Related]
11. Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Rijavec M; Silar M; Triller N; Kern I; Cegovnik U; Košnik M; Korošec P
Pathol Oncol Res; 2011 Sep; 17(3):691-6. PubMed ID: 21455636
[TBL] [Abstract][Full Text] [Related]
12. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
Kovalev AA; Tsvetaeva DA; Grudinskaja TV
Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
[TBL] [Abstract][Full Text] [Related]
13. High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy.
Yang G; Wang XJ; Huang LJ; Zhou YA; Tian F; Zhao JB; Chen P; Liu BY; Wen MM; Li XF; Zhang ZP
PLoS One; 2015; 10(8):e0135576. PubMed ID: 26270652
[TBL] [Abstract][Full Text] [Related]
14. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
15. Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.
Saijo T; Ishii G; Ochiai A; Yoh K; Goto K; Nagai K; Kato H; Nishiwaki Y; Saijo N
Lung Cancer; 2006 Nov; 54(2):217-25. PubMed ID: 16934364
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
Campa D; Müller P; Edler L; Knoefel L; Barale R; Heussel CP; Thomas M; Canzian F; Risch A
Int J Cancer; 2012 Dec; 131(12):2920-8. PubMed ID: 22473764
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
19. Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy.
Koriyama H; Ishii G; Yoh K; Neri S; Morise M; Umemura S; Matsumoto S; Niho S; Ohmatsu H; Tsuboi M; Goto K; Ochiai A
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1163-70. PubMed ID: 25446816
[TBL] [Abstract][Full Text] [Related]
20. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.
Vesel M; Rapp J; Feller D; Kiss E; Jaromi L; Meggyes M; Miskei G; Duga B; Smuk G; Laszlo T; Karner I; Pongracz JE
Respir Res; 2017 Mar; 18(1):52. PubMed ID: 28340578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
